🇺🇸 Agios Pharmaceuticals, Inc.
Forum topic · AGIO · Company page: financials, ownership and filings
Join the discussion on Agios Pharmaceuticals, Inc.
Loading…
Results announced on 5 November 2026
Agios Pharmaceuticals, Inc. announced results on 5 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $55 million (up 330% from a year earlier) and a net loss of $65 million.
Insider trading in October 2026
Directors and officers of Agios Pharmaceuticals, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $371,112 in 3 trades.
Awards, option exercises and shares withheld for tax are not counted.
Mutual funds: 196 funds hold $642 million
196 mutual funds in 2 countries hold shares of Agios Pharmaceuticals, Inc. worth $642 million, about 31.3% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 109 funds added shares and 65 sold; on balance they sold $13 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.